Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem R&D

This article was originally published in The Tan Sheet

Executive Summary

Consumer products manufacturer will break ground for $2 mil., 10,000 sq. ft. research and development facility in Chattanooga, Tenn. in February. Slated for completion by end of calendar year, facility will be dedicated to creating line extensions for existing products, President & Chief Operating Officer Alec Taylor says. Gold Bond sales are expected to be $40 mil.-$42 mil. in FY 2002, and pHisoderm annual sales are expected in $15 mil.-$17 mil. range, Taylor reports during 1Chattem's presentation at Banc of America Securities conference Jan. 10...

You may also be interested in...



Chattem R&D

Mid-November completion of firm's $2 mil., 10,000 sq. ft. R&D facility in Chattanooga, Tenn. was about three weeks ahead of schedule, Chattem says (1"The Tan Sheet" Jan. 20, 2003, In Brief). In line with increased R&D efforts over the past two years, the firm is set to launch BullFrog Mosquito Coast, which combines sun screen with insect repellent and is designed to last six to eight hours (2"The Tan Sheet" Sept. 22, 2003, p. 4)...

Chattem Dexatrim, pHisoderm, Icy Hot Extensions Shipping In Coming Months

Chattem is gearing up to launch a slew of product line extensions in the next few months as its decision to increase its investment in R&D over the past two years begins to pay dividends

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel